The Many Faces of Bleeding Disorders: Inclinix and Inspiration Participate in World Hemophilia Day

WILMINGTON, N.C., April 15 /PRNewswire/ -- You may have heard of hemophilia but did you know that there are many other inherited bleeding disorders?

• Bleeding disorders can affect both males and females;
• von Willebrand disease is the most common bleeding disorder;
• Carriers of hemophilia can also experience bleeding complications;
• Women might not know they have a bleeding disorder until they experience complications with childbirth;
• Most people around the world with bleeding disorders do not have access to adequate diagnosis and treatment.

On World Hemophilia Day 2010, April 17, meet the many faces of bleeding disorders - united to achieve Treatment for All. Each year hemophilia organizations around the world observe World Hemophilia Day in order to increase awareness of hemophilia and other bleeding disorders.

"The goal of the World Federation of Hemophilia is that, one day, treatment will be available for all those with inherited bleeding disorders, regardless of where they live," said Mark Skinner, World Federation of Hemophilia (WFH) president. "Our vision of Treatment for All means expanding services beyond hemophilia, to those with von Willebrand disease, rare factor deficiencies, and inherited platelet disorders."

Hemophilia occurs in approximately 1 in 10,000 male births. It is estimated that over 400,000 people worldwide live with hemophilia, of which only 25% currently receive therapy.

"Inspiration is working hard to be positioned to support the WFH goal to bring quality hemophilia care to all regions of the world by introducing our IB1001 recombinant Factor IX as soon as possible" said Dr. Mike Griffith, Inspiration's CEO.  "Our collaboration with Inclinix is directed at expediting the registration process to achieve this goal."

"On World Hemophilia Day we want to help spread the message that most people around the world with bleeding disorders do not have access to adequate diagnosis and treatment," states  J. Tobin Geatz, Inclinix CEO.  "And that to participate in addressing these shortfalls, Inclinix is proud to partner with Inspiration to contribute to the success of their recombinant Factor IX Clinical Research Study. This study is currently enrolling patients at sites nationwide in an effort to bring forward an additional treatment for persons with Hemophilia B."  For more information please visit www.Factor9hemophiliastudy.com or www.clinicaltrials.gov (reference trial ID of NCT00768287).

About hemophilia and other bleeding disorders

Hemophilia, von Willebrand disease, and other factor deficiencies are lifelong bleeding disorders that prevent blood from clotting properly. People with bleeding disorders do not have enough of a particular clotting factor, a protein in blood that controls bleeding, or it does not work properly. The severity of a person's bleeding disorder usually depends on the amount of clotting factor that is missing or not working. People with hemophilia can experience uncontrolled internal bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability, bleeding into major organs, such as the brain, can cause death.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals was founded in 2004 with the mission to revolutionize treatments for hemophilia. The Company is focused on developing products that have the potential to broaden patient access to therapy, including prophylactic use. Greater access and more frequent prophylactic therapy have been shown to reduce complications of the disease and enhance patients' long-term health and quality of life. Underlying the Company's programs is a novel, proprietary manufacturing technology that allows a greater yield of high-quality protein. Inspiration's lead product candidate is an intravenous recombinant factor IX product for the acute and preventative treatment of bleeding in patients with hemophilia B. For further information regarding the Inspiration clinical trial please contact Dr. Martin Lee [email protected].

About Inclinix, Inc.

Inclinix, Inc. connects investigative sites and clinical research study participants with pharmaceutical, biotech, and medical device companies. Headquartered in Wilmington, North Carolina, Inclinix services are offered globally with project staff based in the United States, Sweden, and the United Kingdom.  Inclinix's proprietary process for developing Enrollment-Ready Sites, supported by Performance Enrollment outreach strategies and leading-edge technology solutions, meets the challenges of clinical development and contributes to successful outcomes.

About the World Federation of Hemophilia (WFH)

The World Federation of Hemophilia is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders. Established in 1963, it is a global network of patient organizations in 113 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.

For more information:

Visit www.Factor9Hemophiliastudy.com

SOURCE Inclinix, Inc.